Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | RAB9A | P51151 | 7/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 4/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MITF | O75030 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15942872 | 0.86 | MEN1 (0.45) | KMT2AMEN1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL14667409 | 0.80 | MAPT (0.55) | KMT2ARAB9AMAPTNPC1SMN1; SMN2 | |
| SCHEMBL14667403 | 0.80 | SORT1 (0.43) | KMT2AMEN1SMN1; SMN2LMNA | |
| SCHEMBL14667396 | 0.78 | HTT (0.40) | KMT2AMEN1MAPTLMNAL3MBTL1 | |
| SCHEMBL14667393 | 0.78 | MAPK1 (0.54) | KMT2ARAB9AMAPTNPC1SMN1; SMN2 | |
| SCHEMBL14667397 | 0.78 | ALDH1A1 (0.44) | KMT2AMEN1MAPTSMN1; SMN2LMNA | |
| SCHEMBL16478650 | 0.77 | RAB9A (0.62) | KMT2AMEN1RAB9AMAPTNPC1 | |
| SCHEMBL15942857 | 0.76 | ROCK1 (0.43) | KMT2AMEN1 | |
| SCHEMBL15986684 | 0.75 | L3MBTL1 (0.54) | KMT2AMEN1RAB9AMAPTNPC1 | |
| SCHEMBL31532609 | 0.74 | RAB9A (0.58) | KMT2AMEN1RAB9AMAPTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8802448-B2 | Mixed mode ligands | PALL CORPORATION (US) | 2014-08-12 | — | — | US | disclosed |
| US-20130030154-A1 | MIXED MODE LIGANDS | PALL CORPORATION (US) | 2013-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130030154-A1 | MIXED MODE LIGANDS | NCL, NECTIN4, NCLN | KMT2A 2278/4885MEN1 1264/4885RAB9A 3439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.